iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm Holdings (IRTC) will release its third-quarter 2026 financial results after trading closes on November 5, 2026.
Management will host a corresponding conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available in the Quarterly Results section at investors.irhythmtech.com.
iRhythm Holdings (Nasdaq: IRTC) completed its acquisition of VitalConnect, broadening its cardiac monitoring portfolio across ambulatory, inpatient and hospital-to-home care. Purchase consideration included $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet, and up to 423,334 shares issued in connection with closing. iRhythm also provided $10.0 million in working capital funding to VitalConnect between signing and closing.
The acquisition adds mobile cardiac telemetry, which remotely monitors heart activity, and multi-vitals monitoring capabilities, extending iRhythm’s reach into inpatient, remote and hospital-to-home settings. iRhythm expects the transaction to enhance its revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for that year.
iRhythm (IRTC) has begun notifying affected individuals after completing its forensic investigation and data review of the previously disclosed cybersecurity incident. Certain stored data was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026 through third-party-hosted business applications. The affected data includes patient names, contact details, account and insurance numbers, device serial numbers, service dates and birth dates.
Notifications began October 2, 2026 for affected individuals whose contact information is held. No impact has been identified on products, clinical systems, customer connections, operations or patient safety. The company continues to believe a material financial impact is not reasonably likely.
iRhythm Holdings (NASDAQ: IRTC) announced its participation in the Wells Fargo 21st Annual Healthcare Conference. Company management is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. ET. A live and archived webcast of the fireside chat will be available via the “Events & Presentations” section of iRhythm’s investor website.
iRhythm (Nasdaq: IRTC) agreed for its subsidiary to acquire privately held VitalConnect for approximately $287.5 million, comprising about $237.5 million in cash funded from existing cash and roughly $50 million in iRhythm common stock. VitalConnect brings an FDA‑cleared wearable biosensor platform spanning multiple cardiac monitoring modalities, including mobile cardiac telemetry (MCT), and multi‑vitals monitoring for hospital and remote care.
According to iRhythm, the combination will broaden its ambulatory and inpatient cardiac monitoring portfolio, expand its addressable market and is expected to be accretive to iRhythm’s revenue growth rate beginning in 2027, while preserving its previously communicated 15% adjusted EBITDA margin target for 2027. iRhythm will also provide VitalConnect up to $30 million in interim working capital financing. Closing is targeted by the end of 2026, subject to regulatory and customary conditions.
iRhythm Holdings (NASDAQ: IRTC) reported second quarter 2026 revenue of $224.2 million, up 20.1% year over year, with gross margin of 72.8%, a 160-basis-point increase. GAAP net loss narrowed to $0.4 million, while adjusted net income reached $19.3 million and adjusted EBITDA was $43.3 million, representing a 19.3% adjusted EBITDA margin.
Unrestricted cash, cash equivalents and marketable securities totaled $591.3 million at June 30, 2026. iRhythm entered a definitive agreement to acquire VitalConnect for approximately $287.5 million, received FDA clearance for its third-generation algorithm, and raised full-year 2026 guidance to $880–$890 million in revenue and 13.0%–14.0% adjusted EBITDA margin.
Summary not available.
iRhythm Holdings (NASDAQ: IRTC) will report its second quarter 2026 financial results after the market close on Thursday, August 6, 2026. The company’s management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived webcasts available in the “Quarterly Results” section of its investor website at investors.irhythmtech.com.
iRhythm Holdings (NASDAQ:IRTC) will participate in two upcoming investor conferences in June 2026.
The company is scheduled for the William Blair 46th Annual Growth Stock Conference on June 2, 2026, and the Truist Securities MedTech Conference on June 16, 2026. Live and archived webcasts will be available on its investor website.
iRhythm (NASDAQ: IRTC) reported Q1 2026 results: revenue $199.4M (+25.7% YoY), gross margin 70.9% (+210 bps), and adjusted EBITDA $14.1M (7.1% margin). Unrestricted cash and marketable securities totaled $549.6M at March 31, 2026.
The company raised 2026 guidance to $875M–$885M revenue and adjusted EBITDA margin 12%–13%, citing volume-led growth, gross margin expansion, and continued investments in AI-enabled cardiac solutions.